Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEBSep 27, 2024 · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupixent, which was invented using Regeneron’s proprietary VelocImmune ® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown …
Dupixent® (dupilumab) Approved in the U.S. as First and Only …
WEBDupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 …
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant …
WEBSep 11, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEBSep 27, 2024 · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEBSep 27, 2024 · Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay ® program.
Press Release: Dupixent is the first and only biologic to ... - Sanofi
WEBSep 11, 2024 · Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease. If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union. Paris and Tarrytown, NY, September 11, 2024.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBJul 29, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a pivotal Phase 3 trial evaluating Dupixent ® (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU) met its primary and all key secondary endpoints at 24 weeks.
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEBFor Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year. SNY Zacks Rank and Other Stocks to Consider Sanofi currently has a Zacks Rank #2 ...
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBOct 25, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced results from a second Phase 3 trial assessing the investigational use of Dupixent ® (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE).